Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3995-4005

  Onishi, Hideya ^a   Morisaki, Takashi ^b   Baba, Eishi ^a   Nakamura, Mitsunari ^c   Inaba, Syoichi ^d   Kuroki, Hideo ^a   Matsumoto, Kotaro ^a   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Fukuoka General Cancer Clinic   (Japan)

^c Nishibaru Clinic   (Japan)

^d SUWA RED CROSS HOSPITAL   (Japan)

Author keywords

DC; ELISPOT; IFN ; Vaccine; Whole tumor cell

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DENDRITIC CELL VACCINE; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 12; IRINOTECAN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3;

ABSENCE OF SIDE EFFECTS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CELL INFILTRATION; CELL MATURATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; LONG TERM CARE; LUNG METASTASIS; MALE; PRIORITY JOURNAL; RECTUM CARCINOMA; RECURRENT CANCER; SKIN TEST; T LYMPHOCYTE; THORAX RADIOGRAPHY; TUMOR BIOPSY; TUMOR CELL; WHOLE TUMOR CELL;

ADULT; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; BONE NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY, ACTIVE; INTERFERON-GAMMA; INTERLEUKIN-12; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 83055195401     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fong L and Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245-273, 2000. (Pubitemid 30365381)
2. Nestle FO, Banchereau J and Hart D: Dendritic cell: On the move from bench to bedside. Nat Med 7: 761-765, 2001. (Pubitemid 32691622)
3. Steinman RM and Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94: 459-473, 2001. (Pubitemid 32979535)
4. Asavaroengchai W, Korera Y and Mule JJ: Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci 99: 931-936, 2002. (Pubitemid 34106613)
5. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM and Black KL: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T cell infiltration. Cancer Res 61: 842-847, 2001. (Pubitemid 32175145)
6. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT and Falo LD Jr.: Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. J Exp Med 85: 283-287, 1996. (Pubitemid 26028768)
7. Boczkowski D, Nair SK, Snyder D and Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-472, 1996. (Pubitemid 26324100)
8. Manickan E, Kanangat S, Rouse RJ, Yu Z and Rouse BT: Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 61: 125-132, 1997. (Pubitemid 27081372)
9. Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH and Whang-Peng J: Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 10: 2645-2651, 2004.
10. Wierecky J, Mueller M and Brossart P: Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55: 63-67, 2006. (Pubitemid 41783295)
11. Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, Lunghi F, Ciceri F, Mukenge S, Doglioni C, Colau D, Coulie PG, Bordignon C, Traversari C and Russo V: Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 113: 1651-1660, 2009.
12. Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, Scharenborg NM, Van De Rakt M, Hesselink EJ, Figdor CG, Adema GJ and Punt CJ: Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 30: 5091-5097, 2010.
13. Rogel A, Vignard V, Bobinet M, Labarriere N and Lang F: A long peptide from MELOE-1 contains multiple HLA class II T-cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunol Immunother 60: 327-337, 2011.
14. Yu JS, Liu G, Ying H, Yong WH, Black KL and Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973-4979, 2004. (Pubitemid 38924545)
15. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, Kang WK, Park K, Choi HY, Lee HM, Baek SY, Lee H, Doh H, Kim BM, Kim CY, Jeon C and Jung CW: Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 125: 257-267, 2007. (Pubitemid 350116707)
16. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI and Lombardi G: Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother 56: 2003-2016, 2007. (Pubitemid 47512607)
17. Toh HC, Wang WW, Chia WK, Kvistborg P, Sun L, Teo K, Phoon YP, Soe Y, Tan SH, Hee SW, Foo KF, Ong S, Koo WH, Zocca MB and Claesson MH: Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin Cancer Res 15: 7726-7736, 2009.
18. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS and Adams DH: A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49: 124-132, 2009.
19. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J and Palucka AK: Cross-priming of naive CD8 T-cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192: 1535-1544, 2000.
20. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987. (Pubitemid 17064313)
21. Zhang H, Morisaki T, Matsunaga H, Sato N, Uchiyama A, Hashizume K, Nagumo F, Tadano J and Katano M: Protein-bound polysaccharide PSK inhibits tumor invasiveness by downregulation of TGF-beta1 and MMPs. Clin Exp Metastasis 18: 343-352, 2000. (Pubitemid 32579404)
22. O'Neil GP and Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330: 156-160, 1993.
23. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, and Mori M: Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85: 713-720, 2001. (Pubitemid 32929470)
24. Krähn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G and Peter RU: Coexpression patterns of EGFR, HER2, HER3, and HER4 in non-melanoma skin cancer. Eur J Cancer 37: 251-259, 2001. (Pubitemid 32144704)
25. Barnett T, Goebel SJ, Nothdurft MA and Elting JJ: Carcinoembryonic antigen family: characterization of cDNAs coding for NCA and CEA and suggestion of nonrandom sequence variation in their conserved loop-domains. Genomics 3: 59-66, 1988.
26. Onishi H, Morisaki T, Baba E, Kuga H, Kuroki H, Matsumoto K, Tanaka M and Katano M: Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol 105: 286-295, 2002. (Pubitemid 36016056)
27. Onishi H, Morisaki T, Kuroki H, Matsumoto K, Baba E, Kuga H, Tanaka M and Katano M: Evaluation of a dysfunctional and short-lived subset of monocyte-derived dendritic cells from cancer patients. Anticancer Res 25: 3445-3451, 2005. (Pubitemid 41105223)
28. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S and Bhardwaj N: Consequences of cell death:Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423-434, 2000.
29. Onishi H, Kuroki H, Matsumoto K, Baba E, Sasaki N, Kuga H, Tanaka M, Katano M and Morisaki T: Monocyte-derived dendritic cells that capture dead tumor cells secrete IL-12 and TNF-alpha through IL-12/TNF-alpha/NF-kappaB autocrine loop. Cancer Immunol Immunother 53: 1093-1100, 2004. (Pubitemid 39506398)
30. Steinman RM, Turley S, Mellman I and Inaba K: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191: 411-416, 2000.
31. Dhodapker MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF and Bhardwaj N: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104: 173-180, 1999.
32. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N and Schuler G: Rapid induction of tumor-specific type 1 T-helper cells in metastatic melanoma patients by vaccination with mature cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195: 1279-1288, 2002. (Pubitemid 34564330)